Department of Urology, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Radiation Oncology, Dalhousie University, Halifax, Nova Scotia, Canada.
Department of Urology, Dalhousie University, Halifax, Nova Scotia, Canada.
Eur Urol. 2023 Jun;83(6):561-570. doi: 10.1016/j.eururo.2023.02.009. Epub 2023 Feb 22.
Although survival rates for newly diagnosed prostate cancer patients are very high, most of them will likely suffer significant treatment-related side effects, depression, or anxiety, affecting their quality of life.
The aim of this study was to examine the effects of a 6-mo online home-based physical, mental, and social support intervention, the Prostate Cancer Patient Empowerment Program (PC-PEP), on preventing psychological distress among men undergoing curative prostate cancer treatment.
DESIGN, SETTING, AND PARTICIPANTS: In a crossover randomized clinical trial of 128 men aged 50-82 yr scheduled for curative prostate cancer surgery or radiotherapy (± hormone treatment), 66 received the 6-mo PC-PEP intervention and 62 were randomized to a waitlist-control arm and received the standard of care for 6 mo, and then PC-PEP to the end of the year. The PC-PEP intervention consisted of daily e-mails with video instructions providing education, patient activation, and empowerment on healthy living including physical and mental health, dietary recommendations, social support, physical and pelvic floor fitness, stress reduction using a biofeedback device, social connection and intimacy, and social support.
The primary outcome was nonspecific psychological distress (clinical cutoff ≥20) measured at baseline, and at 6 and 12 mo using the Kessler Psychological Distress Scale (K10).
At 6 mo, patients in the waitlist-control group had 3.59 (95% confidence interval: 1.12-11.51) times higher odds for nonspecific psychological distress and need for psychological treatment than men who received the PC-PEP intervention. At 12 mo, the wait-list control group that received the intervention at 6 mo had higher psychological distress than the early group.
PC-PEP delivered early following diagnosis significantly prevented the burden of psychological distress in men undergoing curative prostate cancer treatment compared with standard of care, or late (6 mo later) intervention.
In this report, we looked at the effectiveness of a program (Prostate Cancer Patient Empowerment Program: PC-PEP) developed with patients' engagement on the mental distress of patients awaiting curative treatment for their prostate cancer. The PC-PEP program lasted for 6 mo, and it prescribed, described, and demonstrated daily aerobic and strength training, kegels (pelvic floor training to help with urinary and sexual function), dietary changes that have been shown to be helpful in the prevention of prostate cancer and prostate cancer progression, stress reduction using a biofeedback device, as well as social and emotional support. All patients in the PC-PEP program were invited to a monthly video conference with the leads of the program who appeared in the 6 mo of daily videos prescribing the activities the patients were asked to watch and follow. The leads were a prostate cancer oncologist and a scientist in prostate cancer quality of life research. Half of the patients in this study received PC-PEP daily for the first 6 mo and were re-assessed at the end of the year. The other half received standard of care for 6 month and then received the intervention to the end of the year. The results of the study show that, at 6 mo, this intervention was effective at reducing the mental distress that accompanies a prostate cancer diagnosis and treatment compared with the standard of care. Mental distress was significantly reduced when the intervention was received early, compared with that received late (6 mo after scheduled curative treatment). We conclude that multi-faceted patient education and empowerment programming of this kind that is developed with patient engagement from the start is crucial to the care of patients diagnosed with prostate cancer and should be implemented in the standard of care. While treatment for prostate cancer is highly successful, side effects that accompany most treatments significantly affect the quality of life of patients. Here, we describe PC-PEP, a patient education and activation program that is cost effective, highly enforced by patients, and successful at reducing the impact of prostate cancer active treatment-related side effects on their psychological state. To learn more about this project, please visit www.pcpep.org. The program is now being tested in a phase 4 implementation trial throughout Canada and internationally (New Zealand), and is being expanded and tested for other types of cancer.
尽管新诊断出前列腺癌患者的存活率非常高,但他们中的大多数人可能会遭受严重的治疗相关副作用、抑郁或焦虑,从而影响他们的生活质量。
本研究旨在检验为期 6 个月的在线家庭基础身体、心理和社会支持干预措施,前列腺癌患者赋权计划(PC-PEP),对接受根治性前列腺癌治疗的男性预防心理困扰的效果。
设计、地点和参与者:在一项 128 名 50-82 岁男性的交叉随机临床试验中,这些男性计划接受根治性前列腺癌手术或放疗(±激素治疗),其中 66 名男性接受了 6 个月的 PC-PEP 干预,62 名男性被随机分配到等待名单对照组,并在 6 个月内接受标准护理,然后接受 PC-PEP 治疗至年底。PC-PEP 干预包括每天通过电子邮件发送视频指导,提供有关健康生活的教育、患者激活和赋权,包括身体和心理健康、饮食建议、社会支持、身体和骨盆底健身、使用生物反馈设备减轻压力、社交联系和亲密关系以及社会支持。
主要结果是使用 Kessler 心理困扰量表(K10)在基线、6 个月和 12 个月时测量的非特异性心理困扰,K10 为 20 分以上表示心理困扰。
在 6 个月时,等待名单对照组的患者出现非特异性心理困扰和需要心理治疗的可能性是接受 PC-PEP 干预患者的 3.59 倍(95%置信区间:1.12-11.51)。在 12 个月时,6 个月时接受干预的等待名单对照组的心理困扰高于早期组。
与标准护理或晚期(6 个月后)干预相比,在接受根治性前列腺癌治疗前早期接受 PC-PEP 显著降低了男性的心理困扰负担。
在本报告中,我们研究了一种与患者合作开发的计划(前列腺癌患者赋权计划:PC-PEP)对等待根治性治疗前列腺癌的患者的精神困扰的有效性。PC-PEP 计划持续 6 个月,规定、描述和演示了日常有氧运动和力量训练、凯格尔运动(帮助改善尿失禁和性功能的骨盆底训练)、已被证明有助于预防前列腺癌和前列腺癌进展的饮食改变、使用生物反馈设备减轻压力,以及社会和情感支持。PC-PEP 计划的所有患者都被邀请参加每月一次的视频会议,与计划的领导者一起,他们出现在每天规定的活动视频中,指导患者观看和遵循。这些领导者是一位前列腺癌肿瘤学家和一位前列腺癌生活质量研究方面的科学家。本研究的一半患者在头 6 个月接受了每日 PC-PEP,并在年底进行了重新评估。另一半患者在 6 个月内接受了标准护理,然后接受了干预治疗至年底。研究结果表明,在 6 个月时,与标准护理相比,这种干预措施在降低前列腺癌诊断和治疗伴随的心理困扰方面是有效的。与晚期(计划的根治性治疗后 6 个月)相比,早期接受干预显著降低了心理困扰。我们得出结论,这种从一开始就与患者合作开发的多方面患者教育和赋权计划对于诊断为前列腺癌的患者的护理至关重要,应该纳入标准护理。虽然前列腺癌的治疗成功率很高,但大多数治疗方法所带来的副作用会显著影响患者的生活质量。在这里,我们描述了 PC-PEP,这是一种患者教育和激活计划,具有成本效益,患者高度遵守,并且成功地降低了前列腺癌活性治疗相关副作用对其心理状态的影响。欲了解更多关于该项目的信息,请访问 www.pcpep.org。该计划目前正在加拿大和国际上(新西兰)进行第四阶段实施试验,并正在扩大并用于其他类型的癌症。